Infuplas

Magnesium chloride hexahydrate, potassium chloride, sodium chloride and sodium lactate, the active ingredients in Infuplas, are an electrolyte replacement solution presented as a sterile solution for injection for intravenous use. It restores electrolyte balance and plasma volume in patients experiencing electrolyte depletion, fluid loss, or requiring maintenance of plasma osmolarity.

GNH USA supplies Infuplas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution, including temperature‑controlled shipping where required.

Infuplas is used as an electrolyte replacement solution to correct fluid and electrolyte imbalances. - Electrolyte depletion: restores magnesium, potassium, sodium and lactate levels to support cellular function. - Fluid loss: provides isotonic fluid to maintain intravascular volume during dehydration or surgery. - Maintenance of plasma osmolarity: helps keep plasma osmolarity within normal range in critically ill patients.

Infuplas may be associated with infusion‑related adverse reactions.

Common Side Effects: - Injection site pain: mild discomfort or tenderness at the catheter site. - Hypernatremia: elevated sodium levels causing thirst or mild edema. - Hyperkalemia: increased potassium that may produce muscle weakness. - Hypotension: transient drop in blood pressure during rapid infusion. - Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects: - Severe hyperkalemia: risk of cardiac arrhythmia requiring immediate medical attention. - Anaphylactic reaction: rare hypersensitivity with rash, bronchospasm or hypotension. - Metabolic acidosis: unlikely but possible if lactate metabolism is impaired. - Electrolyte imbalance: extreme shifts leading to neurological symptoms. - Hemolysis: rare occurrence due to osmotic changes.

When using Infuplas, clinicians should observe specific precautions to ensure patient safety. - Assess electrolyte status: obtain baseline serum magnesium, potassium and sodium levels before infusion. - Adjust infusion rate: avoid rapid administration to prevent sudden shifts in plasma osmolarity. - Monitor cardiac function: observe ECG for arrhythmias in patients with existing heart disease. - Renal function: evaluate kidney function as impaired clearance may exacerbate electrolyte accumulation. - Contraindications: do not use in patients with known hypersensitivity to any component. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Infuplas can interact with certain medications, altering electrolyte balance or cardiovascular stability.

Major Interactions (Avoid): - Digoxin: increased risk of toxicity due to altered potassium levels. - ACE inhibitors or ARBs: may potentiate hyperkalemia when combined with potassium‑rich solutions. - Loop diuretics: concurrent use can cause unpredictable electrolyte shifts.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: monitor blood pressure as combined effects may cause hypotension. - Insulin therapy: insulin drives potassium into cells; monitor serum potassium closely. - Antacids containing sodium: may contribute to hypernatremia if used concurrently.